Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fresolimumab

Drug Profile

Fresolimumab

Alternative Names: GC-1008

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Baylor College of Medicine; Genzyme Corporation; Sanofi Genzyme
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Osteogenesis imperfecta
  • No development reported Fibrosis; Malignant melanoma; Pulmonary fibrosis; Renal cancer
  • Discontinued Focal segmental glomerulosclerosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 15 Jul 2017 Phase-I clinical trials in Osteogenesis imperfecta in USA (IV) (NCT03064074)
  • 27 Feb 2017 Baylor College of Medicine in collaboration with Genzyme plans a phase I trial for Osteogenesis imperfecta in USA (NCT03064074)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top